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lmmunoreactivity for p53 protein was assessed in 100 cases of 
primary renal-cell carcinoma (RCC). The results were corre- 
lated with clinical survival data (follow-up 24 to 84 months; 
mean: 39 months) and with clinico-pathological parameters, 
including nuclear grade, turnour stage, cell type, tumour archi- 
tecture and tumour diameter. In all, 32% of the tumours were 
p53-positive; there was no difference in survival between p53- 
positive and -negative cases. Similarly, p53 expression did not 
correlate with any of the clinico-pathological parameters men- 
tioned. Nuclear grade (grade I + 2 YI. grade 3 + 4) had a 
striking impact on prognosis and so, to a lesser extent, did 
tumour stage and the occurrence of a spindle-cell component. 
The immunohistochemical detection of p53 in RCC is not of 
prognostic value. The estimation of nuclear grade, however is a 
major predictor of prognosis. 
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Progress through the cell cycle is controlled by positive and 
negative regulatory substances. An important negative regula- 
tor is the p53 protein. Originally discovered in SV40- 
transformed tumour cells, the p53 gene is now regarded a 
major tumour-suppressor gene (Levine et al., 1991). The p53 
gene is localized on the short arm of chromosome 17 (17p) 
(McBride et al., 1986). A mutation in the gene may result in an 
altered protein that has lost its negative regulatory effect. In 
contrast to wild-type p53 protein, point-mutated p53 protein 
can usually be detected immunohistochemically in paraffin- 
embedded material (Porter et al., 1992). Immunohistochemi- 
cally detectable p53 has, in some studies, been linked to a 
worse prognosis (Harris and Holstein, 1993). 
Renal-cell carcinoma (RCC) is a tumour with several 
histologically distinct subtypes related to more or less specific 
cytogenetic defects, e.g. a deletion at chromosome 3p in 
clear-cell RCC (Kovacs et al., 1989; Ogawa et al., 1991; Presti et 
al., 1991). Limited data are available regarding mutations in 
the p53 gene in RCC (Oka et al., 1991). Using polymerase 
chain reaction and single-strand conformational polymor- 
phism analysis of RNA, Torigoe et al., (1992) concluded that 
p53 mutations occur in only 10% of RCC. Deletions at 17p are 
found in a sizeable number of RCCs (Presti e f  al., 1991; Ogawa 
et al., 1992). In 2 studies, deletions at  17p in RCC were 
associated with granular cell type (generally associated with a 
worse prognosis) (Presti et al., 1991) and higher tumour grade 
(Ogawa et al., 1992). This would fit the hypothesis that loss of 
p53 cell-cycle control in RCC may lead to  a more malignant 
phenotype which would show immunoreactivity for p53 pro- 
tein, We therefore performed an immunohistochemical study 
on p53 protein using archival paraffin-embedded samples of 
100 cases of RCC and examined the relation of p53 protein 
with established prognostic factors and with survival. In this 
way, we hoped to determine the validity of immunohistochemi- 
cal assessment of p53 protein as a prognostic factor. 
MATERIAL AND METHODS 
Clinical details and tissue preparation 
A total of 118 RCC specimens from patients treated in the 
University Hospital, Dijkzigt, in the 5-year period 1985-1990, 
wer-e examined. The follow-up period ranged from 24 to 92 
months (mean: 39 months; median: 34 months). Eighteen 
patients were excluded because of loss to follow-up or insufi- 
cient material, leaving 100 patients for analysis. In total, 87 
patients were treated by complete nephrectomy and 13 were 
treated by partial nephrectomy or tumour enucleation. In 
some cases, lymph-node dissection was performed as well. No 
pre-operative treatment directed at the tumour was given. 
Clinico-pathological details of patients and tumours are sum- 
marized in Table I. Tumour cell type was categorized as either 
clear-cell, granular-cell, spindle-cell or oncocytic, according to 
standard pathological criteria. Architecture was categorized as 
papillary or non-papillary, the latter including solid, trabecular 
or tubulo-acinar subtypes. When a tumour was of mixed type it 
was classified according to  the appearance of the dominant 
part. 
The Fuhrman system of nuclear grading (Fuhrman et al., 
1982) and the UICC TNM system for tumour staging were 
employed. 
The specimens had been routinely processed, including 
fixation in 10% buffered formalin and embedding in paraffin 
wax. For each tumour a representative tissue block was 
selected from the archives. Whenever possible this tissue block 
contained uninvolved kidney tissue as well, for purposes of 
comparison. Follow-up data for each patient were drawn from 
the hospital charts. 
Immunohistochemistty 
The monoclonal antibody DO-7 (DAKO, Glostrup, Den- 
mark) was used throughout the studies. This antibody was 
designed for the immunohistochemical detection of p53 in 
paraffin-embedded human material and is produced by a 
hybridoma from mice immunized with recombinant human 
wild-type p53 (VojtESeket al., 1992); it detects wild-type as well 
as mutant p53. DO-7 was tested in dilutions ranging from 15 
to 1:200. A dilution of 1:25 was found to give the optimal signal 
to noise (= non-specific staining) ratio. In 10 cases, available 
frozen tumour material was compared with the formalin-fixed 
material, yielding similar results. 
Briefly, 5-pM sections were cut, mounted on 3-amino 
propyltrioxy-silane (Sigma)-coated glass slides and heat-fmed 
in an incubator overnight at 37°C. The slides were then 
deparaffinized in xylene, rinsed with alcohol and incubated for 
10 min in 3% H 2 0 2  in methanol to block endogenous peroxi- 
dase activity. After a thorough wash in water, the antigen 
retrieval method described by Shi et al. (1991) and modified for 
p53 detection by one of us (K.S.K.) was employed. To this end, 
the slides were immersed in deionized water and heated in a 
microwave oven (700 W power) to 100°C for 2 x 5 min. 
Between each period of heating, evaporated fluid was replen- 
ished. After a 25-min cooling period, the slides were rinsed in 
PBS and preincubated in 10% rabbit serum in PBS for 30 min 
at  room temperature. Then DO-7 was applied (1:25, in PBS) 
and the slides were stored overnight a t  4°C. 
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TABL,E I - p53 EXPRESSION I N  RCC VERSUS CLINICO-PATHOLOGICAL 
CHARACTERISTICS 
Characteristic Number p53 positive (96) 
Total 100 32 (32)’ 
Sex: 
Male 
Female 
Diameter: 
~5 cm 
5-10 cm 
> 10 cni 
Clear cell 
Granular cell 
Spindle cell 
Oncocytic 
Architecture: 
Papillary 
Non-papillary 
Nuclear grade: 
GI 
G2 
G3 
G4 
Cell type: 
66 
34 
23 35 
9 M 
40 16 (40) 
44 11 (25j 
16 5 (31) 
74 
18 
- 7  
1 
14 
86 
22 
45 
26 
7 
Tumor stage: 
T2 54 10 1: [:ill T1 
T3 36 11 (31 
Total nephrectomy 87 25 (29) 
Tumor enucleation / 
Treatment 
13 7 (54) partial nephrectomy 
’18 of moderate, 7 of strong and 7 of very strong intensity. 
After the overnight incubation with DO-7, the slides were 
washed in PBS and monoclonal rabbit anti-mouse antibody 
(1:50 in PBS/5% BSA) was applied for 30 min at  room 
temperature. Following washing in PBS, the third-step reagent 
consisted of monoclonal mouse peroxidase-anti-peroxidase 
complex (PAP) (1 : lOO in PBS) for 30 min at room temperature 
again followed by a PBS wash. The slides were then developed 
using 3,3’-diaminobenzidinetetrahydrochloride (DAB) as sub- 
strate and lightly counterstained with Mayer’s haematoxylin. 
Control slides were prepared, omitting the primary antibody, 
and consistently found to be negative. The PAP system was 
preferred to a biotinylated system because of the presence of 
endogenous biotin activity in kidney (and tumour) tissue. 
Analysis 
p53 staining was typically nuclear, and classified as either 
non-existent or weak, of moderate, strong or very strong 
intensity. In the majority of tumours the staining pattern was 
heterogeneous. A tumour was considered positive when in a 
field at 2 5 0 ~  magnification at least 50% of the nuclei were at  
least moderately positive. Cytoplasmic staining was not ob- 
sewed. 
Survival curves were made using Kaplan-Meier analysis, and 
compared with the log-rank test. The differences in p53 scores 
between subgroups of RCC were tested for significance with a 
Chi-square test. 
RESULTS 
p53 protein expression 
A typical example of p53 immunostaining of RCC is shown 
in Figure 1. The results of the immunohistochemical staining 
of p53 protein in relation to clinicopathological parameters are 
summarized in Table I. 
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FIGURE 1 -Typical renal-cell carcinoma with a majority of the 
nuclei staining dark brown/black indicating p53 immunoreactivity. 
Scale bar, 20 pm. 
A total of 32 tumours were p53-positibe (32%) (18 of 
moderate, 7 of strong and 7 of very strong intensity) and 68 
were p53-negative. Normal kidney never showed positive 
reactivity with anti-p53. No significant difference in p53 
reactivity was seen between tumours composed of diverse cell 
types or between tumours with papillary versus non-papillary 
architecture. Among different classes of nuclear grade, no 
statistically significant difference in p53 reactivity was noted. 
This was also the case when low-grade (G1 + G2) tumours 
were compared with high-grade (G3 + G4) tumours (a > 0.2). 
Equally, T-category, sex of patient and tumour diameter did 
not correlate with p53 expression. In very small tumours 
(diameter of 2.5 cm or less), which by some are regarded as 
adenomas, the distribution of p53-positive and -negative cases 
was analogous to the distribution in larger tumours. When the 
same analysis was performed with only strongly p53-reactive 
tumours rated as positive, the results were identical. This 
eliminates a potential bias due to subjective assessment of 
staining intensity. 
Siiwival analysis 
A Kaplan-Meier survival analysis demonstrated no differ- 
ence in survival between patients with p53-positive tumours 
and those with p53-negative tumours (Fig. 2). Equally, no 
difference in survival could be detected after stratification for 
grade or T-category. 
Among the conventional clinicopathological parameters, 
nuclear grade had the strongest effect on prognosis. Patients 
with G3 and G4 tumours had a significantly lower chance of 
survival than did those with low-grade ( G I  and G2) tumours 
( p  < 0.001) (Fig. 3a). 
T-category was another important determinant of prognosis. 
T1 and T2 tumours (limited to the kidney and differing only in 
size) shared the same prognosis, T3 tumours (extension into 
peri-renal fatty tissue and/or the renal vein) clearly had a 
worse prognosis (p = 0.02) (Fig. 3b). 
Clear-cell type and granular-cell type showed no significant 
difference in survival curves ( p  = 0.2). Spindle-cell type, how- 
ever, was related to a definitely worse prognosis (Fig. 3c). 
No significant differences in survival were found between 
papillary and non-papillary iumours (Fig. 3 4  and with increas- 
ing tumour diameter (data not shown). 
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DISCUSSION 
This study shows that irnmunoreactivity for p53 protein in 
the nuclei of RCC cells is not related to prognosis or to 
established, prognostically relevant, clinico-pathologic parameters. 
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In order to obtain a sufficiently strong p53 signal, the use of 
antigen-retrieval (Shi et aL, 1991). adapted for p53 detection, 
was a necessity in formalin-fixed material, as otherwise hardly 
any p53 reactivity could be detected. Artifacts due to unequal 
duration of furation may play a role in this routinely processed 
material, and could be an explanation for the heterogeneous 
staining pattern in many tumours. 
In several studies on other types of cancer, p53 expression 
emerged as a negative prognostic factor (Harris and Holstein, 
1993). In 2 studies on breast carcinoma, however, p53 expres- 
sion did correlate with unfavourable prognostic factors, but 
not with prognosis (Davidoff et al., 1991; Bosari et al., 1992). 
Furthermore, p53 expression or immunostaining did not corre- 
late with prognosis in laryngeal carcinoma (Dolcetti el al., 
1992), lung carcinoma (McLaren et al., 1992) and breast 
carcinoma (Scott et al., 1991). 
The lack of correlation between p53 staining and prognosis 
in renal-cell carcinoma observed in this study is therefore not 
unique. An explanation for this might be that, in RCC, 
carcinogenesis occurs along a pathway that does not involve 
p53. The predominant type of RCC, the clear-cell carcinoma, 
is characterized by a distinct cytogenetic abnormality: a dele- 
tion on the short arm of chromosome 3 involving a putative 
tumour-suppressor gene (Ogawa et al., 1991; Yamakawa et al., 
1991). This pathway may not require a p53 mutation to confer 
malignant behaviour upon a cell. Presumably, a mutation in 
thep53 gene may occur a t  the same time, but it is not clear as 
yet what its role might be in the development of malignant 
behaviour. 
100 
probability of survival (%) 
8ol 
40 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
20 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . .  
0 
0 12 24 36 48 60 
. . . . . . . . . . . . . .  
. . . . . . . . . . . .  
0 12 24 36 48 60 
months 
FIGURE 3 - Kaplan-Meier survival analysis of RCC, comparing grade 1 + 2 with grade 3 + 4 (a), stage T1, T2 and T3 (b), clear-, 
granular- and spindle-cell type (c) and papillary and non-papillary tumour architecture (d). 
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It must be emphasized that our studies were designed to 
estimate the validity of immunohistochemically detectable p53 
protein as an indicator of prognosis. Since not all mutations in 
the p53 gene result in protein production and we cannot 
completely exclude the detection of wild-type protein, our 
results allow, at best, only limited conclusions regarding 
mutations in the p53 gene. This may also explain the discrep- 
ancy between our results (immunoreactive p53 in 32%) and 
those of Torigoe et al. (1992), who found mutations in only 
10% of cases. 
The papillary type of RCC is reported to exhibit trisomy of 
the short arm of Chromosome 17 (Kovacs et al., 1989; Ogawa et 
al., 1992) which harbours thep53 gene. At the outset of the 
study, we hypothesized that mutation of this gene might be 
involved in the development of this relatively rare type of 
RCC. However, our results do not support this hypothesis. 
Although we could examine only 14 cases of papillary RCC, 6 
(43%) were p53-positive and did not differ significantly from 
non-papillary turnours. Allelic loss at chromosome 17p has 
been found more often in granular-cell tumours (Ogawa et ul., 
1992). As indicated by our results, this is not reflected in a 
higher percentage of p53-immunoreactive tumours in this 
category as compared to  other cell types. The specific associa- 
tion of chromosome 17p loss with granular-cell type was 
recently challenged by Reiter et al. (1993), as they also found a 
substantial number of clear-cell carcinomas with deletions on 
chromosome 17p. These authors observed a p53 mutation in 
33% of the RCC cell lines tested. They concluded that 
abnormalities of thep53 gene are common in RCC and may be 
involved in progression of the tumour. 
In a number of tumours, the appearance of a p53 mutation is 
regarded as a late event in tumorigenesis, resulting in a shift 
towards more malignant behavior (Harris and Holstein, 1993; 
Kaklarnanis et al., 1993). Our data do not support a similar 
mechanism for RCC, since p53 immunoreactivity is not el- 
evated in tumours of higher grade or in a higher T-category. 
Furthermore, among very small RCCs, diameter 2.5 cm or less 
(by some regarded as adenomas) p53 positivity was compa- 
rable to that in larger tumours. 
Of the other pathological parameters, nuclear grade in 
particular was significantly correlated with survival. The distinc- 
tion between grade 2 and grade 3 represents a major impact on 
prognosis. These results confirm previous findings regarding 
the importance of nuclear grading of RCC (Fuhrman et al., 
1982; Gelb et al., 1993). Stage is a well-established prognostic 
factor (Fuhrman et al., 1982): extension into fatty tissue and/or 
the renal vein (T3) resulted in a significantly worse survival. 
There was no difference in prognosis between T1 and T2 cases 
(differing only in size), in accordance with our finding that 
turnour size has no prognostic implications. Survival of pa- 
tients with granular-cell tumours was not different from that of 
patients with clear-cell tumours, although there was a ten- 
dency towards a worse prognosis for the former. This is in 
agreement with previous work suggesting a worse prognosis for 
patients with granular-cell tumours, the latter feature, how- 
ever, not being independent of nuclear grade (Fuhrman et al., 
1982). 
In conclusion, p53 immunoreactivity in RCC does not 
correlate with any subgroup of RCC, has no impact on 
prognosis and therefore is of no use in defining RCC progno- 
sis. The best microscopical variable remains nuclear grade, 
which has a strong impact on prognosis. 
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